oxybutynin has been researched along with propranolol in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (5.88) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (11.76) | 29.6817 |
| 2010's | 13 (76.47) | 24.3611 |
| 2020's | 1 (5.88) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Fijorek, K; Glinka, A; Mendyk, A; Polak, S; Wiśniowska, B | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Applebaum, SM | 1 |
| de Quintana-Sancho, A; Gónzalez-López, MA; López-Sundh, AE; Naharro-Fernández, C; Reguero-Del Cura, L | 1 |
| Casiraghi, A; Cilurzo, F; Gennari, CG; Minghetti, P; Montanari, L; Selmin, F | 1 |
| Fang, L; Li, S; Liu, C; Quan, P; Zhao, Y | 1 |
| Ali, HE; Mahmoud, GA; Mohamed, HA; Radwan, RR | 1 |
| Fang, L; Liu, C; Quan, P; Wan, X; Yang, D | 1 |
| Cilurzo, F; Fedele, G; Franzé, S; Minghetti, P; Musazzi, UM | 1 |
| Chopra, H; Kumar, P; Singh, I | 1 |
2 review(s) available for oxybutynin and propranolol
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Pharmacologic agents in micturitional disorders.
Topics: Baclofen; Bethanechol Compounds; Dantrolene; Dicyclomine; Ephedrine; Flavoxate; Guanethidine; Humans; Imipramine; Mandelic Acids; Methyldopa; Neostigmine; Phenoxybenzamine; Phentolamine; Phenylephrine; Phenylpropanolamine; Propantheline; Propranolol; Quaternary Ammonium Compounds; Urinary Bladder; Urination Disorders | 1980 |
15 other study(ies) available for oxybutynin and propranolol
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
Topics: Artificial Intelligence; Calcium Channel Blockers; Calcium Channels, L-Type; Cell Line; Computational Biology; Computer Simulation; Drugs, Investigational; Ether-A-Go-Go Potassium Channels; Expert Systems; Heart Rate; Humans; Models, Biological; Myocytes, Cardiac; NAV1.5 Voltage-Gated Sodium Channel; Potassium Channel Blockers; Quantitative Structure-Activity Relationship; Risk Assessment; Shaker Superfamily of Potassium Channels; Torsades de Pointes; Voltage-Gated Sodium Channel Blockers | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
Successful treatment of idiopathic Harlequin Syndrome with oxybutynin and propranolol.
Topics: Autonomic Nervous System Diseases; Female; Flushing; Humans; Hypohidrosis; Mandelic Acids; Middle Aged; Parasympatholytics; Propranolol; Vasodilator Agents | 2021 |
Formulation study of a patch containing propranolol by design of experiments.
Topics: Administration, Cutaneous; Adrenergic beta-Antagonists; Animals; Chemistry, Pharmaceutical; Delayed-Action Preparations; Drug Delivery Systems; Epidermis; Excipients; Feasibility Studies; Humans; Male; Permeability; Propranolol; Rats; Skin; Skin Absorption; Skin Irritancy Tests; Time Factors; Transdermal Patch | 2014 |
A systemic evaluation of drug in acrylic pressure sensitive adhesive patch in vitro and in vivo: The roles of intermolecular interaction and adhesive mobility variation in drug controlled release.
Topics: Acrylates; Adhesives; Animals; Benzopyrans; Delayed-Action Preparations; Drug Liberation; Excipients; Humans; Male; Models, Molecular; Pressure; Propionates; Propranolol; Rats, Wistar; Thermodynamics; Transdermal Patch | 2017 |
Radiation preparation of L-arginine/acrylic acid hydrogel matrix patch for transdermal delivery of propranolol HCl in hypertensive rats.
Topics: Acrylates; Administration, Cutaneous; Animals; Antihypertensive Agents; Arginine; Blood Pressure; Drug Liberation; Female; Gamma Rays; Hydrogels; Hypertension; Methylprednisolone; Methylprednisolone Acetate; Propranolol; Rats; Skin; Skin Irritancy Tests; Transdermal Patch | 2018 |
The role of carboxyl group of pressure sensitive adhesive in controlled release of propranolol in transdermal patch: Quantitative determination of ionic interaction and molecular mechanism characterization.
Topics: Adhesives; Administration, Cutaneous; Animals; Delayed-Action Preparations; Drug Delivery Systems; Drug Liberation; Excipients; Ions; Male; Molecular Dynamics Simulation; Pressure; Propranolol; Rats; Rats, Wistar; Skin Absorption; Spectroscopy, Fourier Transform Infrared; Transdermal Patch | 2018 |
Design of in vitro skin permeation studies according to the EMA guideline on quality of transdermal patches.
Topics: Adult; Diclofenac; Europe; Female; Government Agencies; Guidelines as Topic; Humans; Middle Aged; Nitroglycerin; Propranolol; Skin; Skin Absorption; Transdermal Patch | 2018 |
Ionic liquid-based transdermal delivery of propranolol: a patent evaluation of US2018/0169033A1.
Topics: Administration, Cutaneous; Humans; Ionic Liquids; Patents as Topic; Propranolol; Skin; Solubility; Transdermal Patch | 2019 |